Amneal Pharmaceuticals Inc (NYSE:AMRX) shares were up 10.5% during mid-day trading on Tuesday . The stock traded as high as $9.50 and last traded at $9.13. Approximately 2,276,502 shares were traded during trading, an increase of 124% from the average daily volume of 1,018,064 shares. The stock had previously closed at $8.26.

Several research analysts recently issued reports on AMRX shares. Cantor Fitzgerald restated a “buy” rating and set a $35.00 price objective on shares of Amneal Pharmaceuticals in a research report on Thursday, February 28th. Leerink Swann downgraded Amneal Pharmaceuticals to a “market perform” rating in a research report on Friday, March 8th. Svb Leerink downgraded Amneal Pharmaceuticals from an “outperform” rating to a “market perform” rating and cut their price objective for the stock from $16.00 to $12.00 in a research report on Friday, March 8th. SunTrust Banks started coverage on Amneal Pharmaceuticals in a research report on Tuesday, March 19th. They set a “buy” rating and a $16.00 price objective for the company. Finally, ValuEngine downgraded Amneal Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Friday, April 5th. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the company. The company currently has an average rating of “Hold” and an average price target of $19.60.

The company has a quick ratio of 1.37, a current ratio of 2.11 and a debt-to-equity ratio of 3.44. The firm has a market cap of $2.56 billion, a price-to-earnings ratio of 9.61, a price-to-earnings-growth ratio of 0.50 and a beta of 1.31.

Amneal Pharmaceuticals (NYSE:AMRX) last issued its quarterly earnings results on Thursday, May 9th. The company reported $0.11 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.18 by ($0.07). The business had revenue of $446.00 million during the quarter, compared to analyst estimates of $438.18 million. Amneal Pharmaceuticals had a negative net margin of 3.75% and a positive return on equity of 32.14%. The company’s revenue was up 4.9% on a year-over-year basis. On average, research analysts expect that Amneal Pharmaceuticals Inc will post 0.95 EPS for the current year.

In other Amneal Pharmaceuticals news, insider Paul Bisaro purchased 17,000 shares of the business’s stock in a transaction on Tuesday, March 12th. The stock was bought at an average cost of $11.97 per share, for a total transaction of $203,490.00. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Peter R. Terreri sold 23,345 shares of the business’s stock in a transaction on Wednesday, March 6th. The shares were sold at an average price of $12.39, for a total value of $289,244.55. The disclosure for this sale can be found here. Insiders acquired a total of 58,000 shares of company stock valued at $590,790 over the last quarter. 26.34% of the stock is currently owned by insiders.

Institutional investors and hedge funds have recently modified their holdings of the business. Bank of New York Mellon Corp grew its stake in shares of Amneal Pharmaceuticals by 5.8% during the 3rd quarter. Bank of New York Mellon Corp now owns 494,535 shares of the company’s stock valued at $10,973,000 after buying an additional 27,206 shares during the period. Legal & General Group Plc grew its stake in shares of Amneal Pharmaceuticals by 20.7% during the 3rd quarter. Legal & General Group Plc now owns 32,695 shares of the company’s stock valued at $726,000 after buying an additional 5,596 shares during the period. Virtu Financial LLC purchased a new stake in shares of Amneal Pharmaceuticals during the 4th quarter valued at $226,000. Zurcher Kantonalbank Zurich Cantonalbank grew its stake in shares of Amneal Pharmaceuticals by 28.3% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,700 shares of the company’s stock valued at $91,000 after buying an additional 1,477 shares during the period. Finally, Quantamental Technologies LLC purchased a new stake in shares of Amneal Pharmaceuticals during the 4th quarter valued at $68,000. Institutional investors own 38.31% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Amneal Pharmaceuticals (AMRX) Trading Up 10.5%” was originally published by Daily Political and is the sole property of of Daily Political. If you are viewing this story on another publication, it was illegally copied and republished in violation of US & international trademark & copyright law. The original version of this story can be read at https://www.dailypolitical.com/2019/05/21/amneal-pharmaceuticals-amrx-trading-up-10-5.html.

Amneal Pharmaceuticals Company Profile (NYSE:AMRX)

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. It operates through two segments, Generics and Specialty. The Generics segment develops, manufactures, and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals across a range of therapeutic categories.

Further Reading: What is the price-sales ratio?

Receive News & Ratings for Amneal Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amneal Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.